Personalized DNA Therapy Designed to Ward Off Cancer Permanently
An innovative clinical research team at The Clatterbridge Cancer Centre in the UK announced on February 4, 2022, they have given a cancer patient an injection of a therapy tailor-made to his personal DNA and designed to help his immune system ward off cancer permanently.
He will have a year-long course of immunotherapy injections in a bid to keep him cancer-free, part of a research project designed to reduce deaths and recurrence in head and neck cancers, including of the throat, neck, mouth, and tongue.
In a news article, the West Kirkby resident said that he was not worried about being the first person in the UK to receive this pioneering treatment and that it "opened new doorways," which gave him hope that cancer would not come back.
"When I had my first cancer treatment in 2011, I was under the impression that cancer would not return."
"My biggest fear was realized in 2016 when it came back and then in 2019 and then two cases in 2021."
Chief Investigator for the UK trial, Professor Christian Ottensmeier, a Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool, commented, "It is a really exciting day in this important and potentially game-changing research."
"To have reached the stage of a patient receiving this treatment that only a few years ago was thought of as science fiction is truly amazing."
Prof Ottensmeier said more patients were joining the trial at Clatterbridge, and they would be offered individualized treatments, which could benefit them greatly, as well as expand the team's knowledge of personalized cancer therapies that could eventually be help people with other cancer types.
The Transgene study, undertaken at Clatterbridge Centre, Liverpool, also involves cancer researchers from Liverpool Head & Neck Centre, Liverpool University Hospitals, and the University of Liverpool.